Tafamidis

Tafamidis, Tafamidis, also known as Fx-1006 or PF-06291826, is a drug for the amelioration of transthyretin-related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease. The drug was approved by the European Medicines Agency in November 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in September 2013. Tafamidis functions by kinetic stabilization of the correctly folded tetrameric form of the transthyretin (TTR) protein.

Product information

CAS Number: 594839-88-0

Molecular Weight: 308.12

Formula: C14H7Cl2NO3

Synonym:

Fx-1006A

Vyndaqel

Fx1006A

Fx 1006A

Chemical Name: 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid

Smiles: OC(=O)C1=CC2OC(=NC=2C=C1)C1C=C(Cl)C=C(Cl)C=1

InChiKey: TXEIIPDJKFWEEC-UHFFFAOYSA-N

InChi: InChI=1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H,(H,18,19)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

Products are for research use only. Not for human use.